Role of Activin A (ActA) in the Human Cancer Cachexia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-05-31

Study Completion Date

2016-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of the investigators study is to investigate the role of a hormone named Activin A (ActA) in the development of the skeletal muscle atrophy caused by cancer. According to the investigators hypothesis, ActA could be released by the tumor and activate a muscle atrophy gene program. To answer this question, the investigators plan first to compare circulating levels of ActA in cancer patients with and without cachexia. In a second step, the investigators would like to assess whether ActA circulating levels are predictive for the development of cachexia and short survival.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

NCT06073431

Advanced Colorectal Carcinoma Advanced Lung Non-Small Cell Carcinoma Advanced Pancreatic Adenocarcinoma +6 more

RECRUITING

Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy

NCT05154474

Metastatic Cancer Cancer, Breast Cancer Colon +12 more

UNKNOWN

Cachexia in NSCLC Patients: Diagnosis, Characterization, Prognosis, Functional and Skeletal Muscle Implications

NCT03960034

NSCLC Stage IV

COMPLETED

Development of a Screening Tool to Detect and Stage Cachectic Cancer Patients

NCT01533909

Cachexia

COMPLETED

Circulating and Molecular Markers Involved in the Processes of Cachexia, Anorexia and Sarcopenia in Patients With NSCLC

NCT06808113

Non Small Cell Lung Cancer

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cachectic versus no cachectic patients

blood tests, muscular biopsies

Group Type OTHER

blood tests and muscular biopsies

Intervention Type OTHER

blood tests and muscular biopsies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood tests and muscular biopsies

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-year-old or older
* Colorectal or lung cancer demonstrated by histology or cytology
* New diagnosis or new recurrence
* Expected survival more than 3 months
* No previous history of other cancer in the last 5 years
* No pregnancy or lactation
* Signed informed consent

Exclusion Criteria

* Non-caucasian
* Major digestive malabsorption
* Major depression
* Artificial nutrition
* Height doses of steroids (\>1 mg/kg hydrocortisone equivalent)
* Hyperthyroidism
* Other causes of malnutrition
* Expected survival less than 3 months
* Severely impaired walking
* Anticoagulants or antiplatelet therapy
* Disability or medical condition which might prevent the compliance to the protocol
* Any conditions which may prevent the compliance to the protocol
* Performance status ECOG \> ou = 4
* Participation to other clinical studies

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No